ChromaDex (CDXC) Projected to Post Earnings on Tuesday

ChromaDex (NASDAQ:CDXC - Get Free Report) will likely be posting its quarterly earnings results after the market closes on Tuesday, March 4th. Analysts expect ChromaDex to post earnings of $0.02 per share and revenue of $26.51 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC traded up $0.20 during midday trading on Friday, hitting $5.64. The company's stock had a trading volume of 429,015 shares, compared to its average volume of 361,900. The business's 50 day simple moving average is $5.61 and its 200 day simple moving average is $5.05. The company has a market cap of $430.80 million, a P/E ratio of 564.56 and a beta of 2.21. ChromaDex has a 12-month low of $1.57 and a 12-month high of $7.97.

Insiders Place Their Bets

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now directly owns 244,179 shares of the company's stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 9.64% of the stock is owned by insiders.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. StockNews.com raised shares of ChromaDex from a "buy" rating to a "strong-buy" rating in a research note on Monday, February 24th. HC Wainwright raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, November 4th. Finally, Roth Mkm raised their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.